DOCSLIB.ORG

Pharmavoice 100 Honorees, Including Our Own Kara Dennis and Steve Smith!

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Celebration InspiredLEADERS By IMPACTING THE LIFE-SCIENCES INDUSTRY September 17, 2015 PHARMAVOICE 100 CELEBRATION 1 Celebrating Innovation and Inspiration in the Life Sciences Congratulations to this year’s PharmaVOICE 100 honorees, including our own Kara Dennis and Steve Smith! We commend PharmaVOICE for showcasing the outstanding work of industry thought leaders for over a decade. Thank you for fostering collaboration across the life sciences and for sharing innovative ideas and insights that are moving our industry forward. Steve Smith Kara Dennis Chief Patient Advocate Managing Director of mHealth [email protected] | mdsol.com | +1 866 515 6044 Celebration WELCOME LETTER he idea behind publication: The Forum for the Industry Executive PharmaVOICE — both — which is why this inaugural Celebration event is so Tmagazine and online — created a special and exciting. We have the opportunity to bring forum for leaders to Read. Think. together and recognize in person the men and women Participate. in the dynamic life-sciences — the PharmaVOICE 100 and Red Jacket honorees — industry. From molecule to market, who are impacting change throughout the life-sciences PharmaVOICE has been providing the industry and who inspire so many people every day. perspectives and insights of passionate We have enjoyed getting to know each and every one and committed thought leaders for of the honorees over the years, and we look forward to nearly 15 years. their inspired leadership for years to come. Taren Grom Editor, PharmaVOICE On the way to an industry trade On behalf of everyone at PharmaVOICE, I want to show, about three years after the thank all of our generous sponsors and attendees who made this event possible. launch of PharmaVOICE, we were We are proud to donate a portion of the proceeds from the event to stuck in the Philadelphia airport. Reach Out And Read, which prepares America’s youngest children to succeed in During what turned into a very, very school by partnering with doctors to prescribe books and encourage families to long delay, we began talking about the read together. people who we were scheduled to meet, how inspired we were by the work they were doing, and the difference they TABLE OF CONTENTS were making in the industry. Like the start of so many great innovations, one Letter from the Editor ...........................................................................3 brainstorming idea led to another, and Agenda ...................................................................................................... 4 upon landing at our destination the Executive Forum Panelists ..................................................................5 following morning, we had also landed Table Curators ..........................................................................................6 on the concept of the PharmaVOICE Red Jacket Honorees — 2014 & 2015 ...............................................8 100. So with an idea that started with PharmaVOICE 100 Celebration Sponsors ...................................10 a special publication that long ago Art of Inspiration ................................................................................... 16 August to celebrate the individuals Building Inspired Teams .................................................................... 24 behind the companies, products, Inspiring Words ......................................................................................30 brands, tools, and services that benefit Inspiring Reads ...................................................................................... 32 patients worldwide, we have now recognized more than 1,000 of the Inspiring Jobs ......................................................................................... 33 industry’s most inspirational leaders Inspired to Give ......................................................................................34 from all sectors of the industry. PharmaVOICE 100 Honorees Through the Years ..................... 36 We view ourselves as a convener — as evidenced by the tagline of our PHARMAVOICE 100 CELEBRATION 3 Celebration AGENDA September 17, 2015 Apella Event Space • Riverpark, a Tom Colicchio Restaurant The Alexandria Center for Life Science TIME EVENT 6:00 pm Registration Opens 6:30 pm – 7:30 pm Executive Forum 7:30 pm – 10:30 pm Networking Event 8:00 pm – 8:30 pm Curated Table Discussions feel INFINITELY IN FEEL DEEPER. We have a lot of heart for what patients and customers go through when it comes Are you interested in a to their healthcare. How do we know how they feel? We dig deep to find out. We engage with them heart-to-heart conversation honestly and through real connections we uncover how they feel inside. Their fears, concerns, with your customers? and sometimes complete disconnection from their own health. Deep down in their hearts patients Call Matt Brown at want to feel that healthcare companies and providers “get them.” Sometimes brand promotion 201-740-6160. and cool tactics aren’t enough. For clients looking to find new ways to engage customers, we also create unique content to help them connect with their customers on a more meaningful level. www.guidemarkhealth.com Celebration EXECUTIVE FORUM PANELISTS JEFFREY S. ARONIN Chairman & CEO, Marathon Pharmaceuticals Mr. Aronin is a business leader, life-science investor, and philanthropist. He is also chairman and CEO of Paragon Pharmaceutical Capital. Before founding Marathon, he founded Ovation Pharmaceuticals Inc. and MATTER, a successful healthcare technology incubator to support entrepreneurs. Mr. Aronin was named a PharmaVOICE 100 honoree in 2005, 2008, and a Red Jacket honoree in 2015. DEBORAH DUNSIRE, M.D. President and CEO, FORUM Pharmaceuticals Dr. Dunsire has more than 25 years of scientific, clinical, operational, and commercial experience, as well as proven leadership in the biotech and pharma industries. Before joining FORUM in 2013, she served as President and CEO of Millennium Pharmaceuticals (now Takeda Oncology) from 2005 to 2013. Dr. Dunsire was named a PharmaVOICE 100 in 2010 and 2014 and a Red Jacket honoree in 2015. RICK KEEFER Global Chief Business Development Officer, Publicis Healthcare Communications Group Mr. Keefer is a 30-year industry veteran with broad-based experience in leading commercial operations. He was named Global Chief Business Development Officer of PHCG in January 2015. He was named a PharmaVOICE 100 in 2008, 2009, 2010, 2011, 2012, 2013, and a Red Jacket honoree in 2014. LEEROM SEGAL Co-Founder & CEO, Klick Health Mr. Segal is Co-founder and CEO of Klick Health, the world’s largest independent health agency. He is also co-author of the New York Times bestseller The Decoded Company: Know Your People Better Than You Know Your Customers. Mr. Segal was named a PharmaVOICE 100 honoree in 2012, 2013, 2014, and a Red Jacket honoree in 2015. CHRISTI SHAW US Country Head, President, Novartis Corp. & Novartis Pharmaceuticals Corp. Ms. Shaw has oversight responsibility for 27,000 associates over six divisions, for whom “More Moments for More Memories” isn’t just a mantra — it’s a mission. Through the lens of innovation, integrity, and inclusion, she leads the US General Medicines business and Novartis Corporation operations. Ms. Shaw was named a PharmaVOICE 100 honoree in 2015. PHARMAVOICE 100 CELEBRATION 5 Celebration TABLE CURATORS LAURIE COOKE, RPH CEO, Healthcare Businesswomen’s Association Ms. Cooke, a senior healthcare industry executive with an extensive career in both pharmaceutical and nonprofit arenas, assumed the role of CEO of the HBA nine years ago. She is well-versed in commercializing insights across the career continuum and drug development from preclinical to post approval. Ms. Cooke was named a PharmaVOICE 100 in 2009. DENISE DEMAN Founder, Chairman & CEO, Bench International With an indefatigable entrepreneurial spirit, Ms. DeMan has taken Bench International from its founding in 1974 to its eminence today as the premiere specialized retained executive search firm focused on life-sciences in the world. She is deeply committed to properly “shattering” the glass ceiling for women in the life-sciences. Ms. DeMan was named a PharmaVOICE 100 in 2009. CHRISTINE PIERRE CEO and Founder, RxTrials Inc. and Founder and President, Society for Clinical Research Sites (SCRS) Ms. Pierre is internationally known for her experience and expertise in clinical research site management and patient recruitment and retention for the clinical trials industry. Ms. Pierre was named a PharmaVOICE 100 in 2009 and 2013. STEPHEN SMITH Chief Patient Advocate, Medidata Solutions Mr. Smith was named chief patient advocate of Medidata Solutions in 2015. He is a staunch advocate for rare disease patients and plays a unique and critical role in the modernization of the clinical trials process, If the odds of lightening striking the same place twice are extraordinary, try three. and serves on the Committee on Federal Legislation for the National MPS Society. Mr. Smith was named a PharmaVOICE 100 in 2015. Congratualtions to our own Michelle Keefe, Matt McNally and Bill Drummy for being honored among the PharmaVOICE 100 most inspiring people. CECI ZAK It’s an honor to work beside you. Chief Operating Officer, Healthcare, DAS-Omnicom Ceci Zak, who before joining DAS-Omnicom in 2013, spent more than 20 years with Sanofi and Roche, most recently in GM roles, where she drove innovative culture and commercial model change while exceeding targets and strategically positioning these companies
Recommended publications
  • 2009: Turning the Corner

    2009: Turning the Corner

    data page 2009: Turning the corner Walter Yang Despite the shaky start to 2009, the biotech sector regained its financial Although initial public offerings showed signs of resuscitation (at least footing. Biotech indices were up, as were offerings and partnership mon- 13 more companies are now in the queue), follow-on financings came in ies. Excluding collaborations, the sector raised a total of $24.3 billion. above $6 billion—the second-best year over the past decade. Stock market performance Global biotech industry financing Although biotech indices were up ~16% last year, they underperformed The boost in partnership promises to US biotechs and follow-on financings other major indices. pushed industry funding to $61.3 billion, up 82% from 2008. 1,500 Swiss Market S&P 500 2009 36.9 10.0 5.1 2.2 6.0 0.9 1,400 NASDAQ Biotech Dow Jones 2008 20.0 3.2 5.3 3.1 1.9 0.1 1,300 NASDAQ BioCentury 100 2007 22.4 11.7 6.8 4.7 4.4 3.0 1,200 Partnering 2006 19.8 11.9 5.6 4.7 5.6 2.0 1,100 Year Debt and other Index 17.3 6.1 5.4 2.7 4.8 1.9 1,000 2005 Venture capital PIPEs 900 2004 10.9 8.8 5.3 2.9 3.3 2.6 Follow-ons 800 2003 8.9 9.1 4.0 2.2 3.9 0.5 IPOs 700 010203040506070 Amount raised ($ billions) 1/09 2/09 3/09 4/09 5/09 6/09 7/09 8/09 9/09 12/08 Month ending 10/09 11/09 12/09 Partnership figures are for deals involving a US company.
  • Overview of Ftc Antitrust Actions in Pharmaceutical Services and Products

    Overview of Ftc Antitrust Actions in Pharmaceutical Services and Products

    OVERVIEW OF FTC ANTITRUST ACTIONS IN PHARMACEUTICAL SERVICES AND PRODUCTS Health Care Division Bureau of Competition Federal Trade Commission Washington D.C. 20580 Markus H. Meier Assistant Director Bradley S. Albert Deputy Assistant Director Saralisa C. Brau Deputy Assistant Director September 2009 TABLE OF CONTENTS Page I. INTRODUCTION. ........................................................... 1 II. CONDUCT INVOLVING PHARMACEUTICAL SERVICES AND PRODUCTS. 3 A. Monopolization. ...................................................... 3 B. Agreements Not to Compete. ............................................ 8 C. Agreements on Price or Price-Related Terms. 14 D. Agreements to Obstruct Innovative Forms of Health Care Delivery or Financing. 20 E. Illegal Tying and Other Arrangements. .................................... 20 III. PHARMACEUTICAL MERGERS. ........................................... 20 A. Horizontal Mergers Between Direct Competitors. 20 B. Potential Competition Mergers. ......................................... 44 C. Innovation Market Mergers. ............................................ 47 D. Vertical Mergers...................................................... 49 IV. INDUSTRY GUIDANCE STATEMENTS...................................... 50 A. Advisory Opinions. ................................................... 50 B. Citizen Petition to the Food and Drug Administration. 51 V. AMICUS BRIEFS. ......................................................... 51 VI. INDICES. ............................................................
  • Schedule 14A

    Schedule 14A

    QuickLinks -- Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material under §240.14a-12 Verastem, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ý No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: o Fee paid previously with preliminary materials. o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  • 1 United States District Court for the Southern District

    1 United States District Court for the Southern District

    Case 1:07-cv-12141-PBS Document 18-3 Filed 11/28/07 Page 1 of 167 UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF IOWA, CENTRAL DIVISION THE STATE OF IOWA, Plaintiff, v. ABBOTT LABORATORIES, INC., AGOURON PHARMACEUTICALS, INC., JURY TRIAL REQUESTED ALPHARMA, INC., ALZA CORPORATION, AMGEN, INC., ASTRAZENECA L.P., ASTRAZENECA PHARMACEUTICALS, LP., AVENTIS BEHRING L.L.C., COMPLAINT BARR LABORATORIES, INC., BAXTER INTERNATIONAL, INC., BAXTER HEALTHCARE CORPORATION, BAYER CORPORATION, BAYER PHARMACEUTICALS CORPORATION, BEN VENUE LABORATORIES, INC., BOEHRINGER INGELHEIM CORPORATION, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC., BRISTOL-MYERS SQUIBB COMPANY, CENTOCOR, INC., CHIRON CORPORATION, DERMIK LABORATORIES, INC., DEY, INC., DEY, L.P., ELI LILLY AND COMPANY, EMD, INC., ENDO PHARMACEUTICALS, INC., ETHEX CORPORATION, ETHICON, INC., FOREST LABORATORIES, INC., FOREST PHARMACEUTICALS, INC. GENEVA PHARMACEUTICALS, GLAXOSMITHKLINE, PLC, GLAXOWELLCOME, INC., GREENSTONE, LTD., HOECHEST MARION ROIUSSEL, INC., HOFFMAN-LAROCHE, INC., 1 Case 1:07-cv-12141-PBS Document 18-3 Filed 11/28/07 Page 2 of 167 IMMUNEX CORPORATION, IVAX CORPORATION, IVAX PHARMACEUTICALS, INC., JANSSEN PHARMACEUTICA PRODUCTS, LP, JOHNSON & JOHNSON, KING PHARMACEUTICALS, INC., KING RESEARCH AND DEVELOPMENT, MCNEIL-PPC, INC., MEDIMMUNE, INC., MERCK & CO., INC., MONARCH PHARMACEUTICALS, INC., MYLAN LABORATORIES, INC., MYLAN PHARMACEUTICALS, INC., NOVARTIS PHARMACEUTICALS CORPORATION, NOVOPHARM USA, INC., ONCOLOGY THERAPEUTICS NETWORK CORP., ORTHO-MCNEIL PHARMACEUTICAL, INC.,
  • 28 May 2009 Thomas E. Costa

    28 May 2009 Thomas E. Costa

    The Third International Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Thomas E. Costa 2828 MayMay 20092009 This presentation represents my own personal opinion and is not the official position of Bristol-Myers Squibb PhRMA Code 2009 • Updated in response to concerns of healthcare stakeholders • Reaffirms that interactions between pharmaceutical company representatives and healthcare professionals (HCPs) should: ¾ Inform HCPs about the benefits and risks of our products ¾ Provide scientific and educational information ¾ Obtain feedback and advice about our products through consultation with medical experts • The PhRMA Code is the new industry standard PhRMA Code Signatory Companies • Abbott • Eli Lilly and Company • Amgen, Inc. • Merck & Company, Inc. • Amylin Pharmaceuticals, Inc. • Millennium Pharmaceuticals, Inc. • Astellas US LLC • Novartis Pharmaceuticals • AstraZeneca LP Corporation • Bayer HealthCare • Novo Nordisk Inc. Pharmaceuticals • Otsuka America, Inc. • Boehringer Ingleheim • Ovation Pharmaceuticals, Inc. Pharmaceuticals, Inc. • Pfizer, Inc. • Bristol-Myers Squibb Company • Purdue Pharma LP • Cephalon, Inc. • sanofi-aventis US • Covidien Ltd. • Schering-Plough Corporation • Daiichi Sankyo, Inc. • Sepracor, Inc. • Eisai, Inc. • Signa-Tau Pharmaceuticals, Inc. • EMD Serono • Solstice Neurosciences, Inc. • Endo Pharmaceuticals, Inc. • Solvay Pharmaceuticals, Inc. • Genzyme Corporation • Takeda Pharmaceuticals North • GlaxoSmithKline America, Inc. • Hoffmann-La Roche, Inc. • Wyeth • Johnson and Johnson
  • Update Covers C1-C4 Iss2 2005.Indd

    Update Covers C1-C4 Iss2 2005.Indd

    In Compliance and In Court by John B. Reiss, Ph.D., and William M. Janssen his article examines various fraud and abuse cases is the simultane- violated the Anti-Kickback Statute. Tlegal issues facing the medical ous fi ling of False Claims Act charges. Under the government’s theory, these device, pharmaceutical, and biologics Because the False Claims Act permits inducements resulted in an illegal use industries; court decisions or settle- fi nes of up to three times the amount of the drugs, and claims fi led for these ments over the past year; and suggested of the claim—and penalties of between uses were thus false. Also brought actions. New guidelines set standards $5,500 and $11,000 per claim—penal- into focus by this case were the False that industry leaders should consider as ties can add up quickly to billions of Claims Act’s qui tam provisions, which they plan product development, sales, dollars, giving the government an enor- allow whistleblowers to participate in and marketing strategies. mous “hammer” with which to exact up to 25% of the government’s recov- settlements. ery. A majority of the recent cases have Fraud and Abuse and the The complexity of the application resulted from whistleblower fi lings. False Claims Act of these laws is demonstrated by the TAP Pharmaceuticals made an Fraud and abuse issues dominated Warner-Lambert case.1 The primary $875 million payment in October 2001, the headlines during 2004. The U.S. allegation involved the company’s partly as the result of its guilty plea for Attorney and the Department of Health off-label marketing of its epilepsy violating the Prescription Drug Market- and Human Services (DHHS) Offi ce of drug, Neurontin®, in violation of the ing Act.2 The government also alleged Inspector General (OIG) continued a Federal Food, Drug, and Cosmetic Act manipulation of the average wholesale high level of activity, and states’ attor- (FDCA).
  • 11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01

    11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01

    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
  • Active Labelers Run Date : Feb 19, 2018

    Active Labelers Run Date : Feb 19, 2018

    Active Labelers Run Date : Feb 19, 2018 Labeler ID Labeler Name Contract Begin Date Contract End Date 00002 ELI LILLY AND COMPANY 01/01/1991 01/01/3000 00003 E.R. SQUIBB & SONS, LLC. 01/01/1991 01/01/3000 00004 HOFFMANN-LA ROCHE 01/01/1991 01/01/3000 00006 MERCK & CO., INC. 01/01/1991 01/01/3000 00007 GLAXOSMITHKLINE 01/01/1991 01/01/3000 00008 WYETH LABORATORIES 01/01/1991 01/01/3000 00009 PFIZER, INC 01/01/1991 01/01/3000 00013 PFIZER, INC. 01/01/1991 01/01/3000 00014 PFIZER, INC 01/01/1991 01/01/3000 00015 MEAD JOHNSON AND COMPANY 01/01/1991 01/01/3000 00023 ALLERGAN INC 01/01/1991 01/01/3000 00024 SANOFI-AVENTIS, US LLC 01/01/1991 01/01/3000 00025 PFIZER, INC. 01/01/1991 01/01/3000 00026 BAYER HEALTHCARE LLC 01/01/1991 01/01/3000 00029 GLAXOSMITHKLINE 01/01/1991 01/01/3000 00032 ABBVIE INC. 01/01/1991 01/01/3000 00037 MEDA PHARMACEUTICALS, INC. 01/01/1991 01/01/3000 00039 SANOFI-AVENTIS, US LLC 01/01/1991 01/01/3000 00046 AYERST LABORATORIES 01/01/1991 01/01/3000 00049 PFIZER, INC 01/01/1991 01/01/3000 00051 ABBVIE INC 10/01/1997 01/01/3000 00052 ORGANON USA INC. 01/01/1991 01/01/3000 00053 CSL BEHRING LLC 01/01/1991 01/01/3000 00054 WEST-WARD PHARMACEUTICALS CORP. 01/01/1991 01/01/3000 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 01/01/1991 01/01/3000 00062 ORTHO MCNEIL PHARMACEUTICALS 01/01/1991 01/01/3000 00064 HEALTHPOINT, LTD.
  • Bioscience Industry Companies This List Includes Georgia Companies That Fall Into the Bioscience Industry, with a Brief Description Shown

    Bioscience Industry Companies This List Includes Georgia Companies That Fall Into the Bioscience Industry, with a Brief Description Shown

    Bioscience Industry Companies This list includes Georgia companies that fall into the bioscience industry, with a brief description shown. Company Name City Description Website Develops novel automated technology for the 3 Ti (Transfusion Transplantation Technologies) Atlanta diagnostic testing of blood associated with blood http://www.3tibio.com/location.html transfusions. Develops 3-D modeling technology for dental 360 Imaging Atlanta http://www.360imaging.com surgeries. Develops real-time 3-D visualization technology for 3D SURGICAL SOLUTIONS Marietta minimally invasive surgeries. Develops and manufactures skin-safe tape for 3M Atlanta healthcare. http://www.3m.com 3R Gloves Roswell Manufactures reusable and recyclable latex gloves. 4P Therapeutics Norcross Manufacturer of drug delivery technologies www.4ptherapeutics.com Manufactures blood pressure monitors, scales, A&D Engineering Duluth www.andonline.com thermometers, and activity monitors. Manufactures and specializes in the production of A&L Shielding Rome www.alshielding.com radiation shielding products. Develops and produces diamond and carbide A&M INSTRUMENTS Alpharetta www.aminstr.com cutting tools. Manufactures hospital air purification equipment Abatement Technologies Suwanee www.abatement.com for infection control. Science based offerings in diagnostics, medical Abbott Laboratories Alpharetta www.abbott.com devices, nutrition, and pharmaceuticals. Bioscience Industry Companies This list includes Georgia companies that fall into the bioscience industry, with a brief description shown. Develops proprietary technology to discover Abeome Athens www.abeomecorp.com therapeutic and diagnostic monoclonal antibodies. Manufactures medical devices and provides Accellent Trenton research for several non-medical industries. Savannah and Augusta Testing services for pharmaceutical and Acuren Inspection www.acuren.com Metro biotechnology companies. Pharmaceutical research focused on cell Aderans Pharmaceutical Research Institute Marietta engineering solutions for hair loss.
  • Why Are Some Generic Drugs Skyrocketing in Price? Hearing Committee on Health, Education, Labor, and Pensions United States Sena

    Why Are Some Generic Drugs Skyrocketing in Price? Hearing Committee on Health, Education, Labor, and Pensions United States Sena

    S. HRG. 113–859 WHY ARE SOME GENERIC DRUGS SKYROCKETING IN PRICE? HEARING BEFORE THE SUBCOMMITTEE ON PRIMARY HEALTH AND AGING OF THE COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS UNITED STATES SENATE ONE HUNDRED THIRTEENTH CONGRESS SECOND SESSION ON EXAMINING THE PRICING OF GENERIC DRUGS NOVEMBER 20, 2014 Printed for the use of the Committee on Health, Education, Labor, and Pensions ( Available via the World Wide Web: http://www.gpo.gov/fdsys/ U.S. GOVERNMENT PUBLISHING OFFICE 24–459 PDF WASHINGTON : 2017 For sale by the Superintendent of Documents, U.S. Government Publishing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2104 Mail: Stop IDCC, Washington, DC 20402–0001 VerDate Nov 24 2008 13:32 May 19, 2017 Jkt 000000 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 S:\DOCS\24459.TXT DENISE HELPN-003 with DISTILLER COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS TOM HARKIN, Iowa, Chairman BARBARA A. MIKULSKI, Maryland LAMAR ALEXANDER, Tennessee PATTY MURRAY, Washington MICHAEL B. ENZI, Wyoming BERNARD SANDERS (I), Vermont RICHARD BURR, North Carolina ROBERT P. CASEY, JR., Pennsylvania JOHNNY ISAKSON, Georgia KAY R. HAGAN, North Carolina RAND PAUL, Kentucky AL FRANKEN, Minnesota ORRIN G. HATCH, Utah MICHAEL F. BENNET, Colorado PAT ROBERTS, Kansas SHELDON WHITEHOUSE, Rhode Island LISA MURKOWSKI, Alaska TAMMY BALDWIN, Wisconsin MARK KIRK, Illinois CHRISTOPHER S. MURPHY, Connecticut TIM SCOTT, South Carolina ELIZABETH WARREN, Massachusetts DEREK MILLER, Staff Director LAUREN MCFERRAN, Deputy Staff Director and Chief Counsel DAVID P. CLEARY, Republican Staff Director SUBCOMMITTEE ON PRIMARY HEALTH AND AGING BERNARD SANDERS, Vermont, Chairman BARBARA A.
  • Beyond Borders Global Biotechnology Report 2010

    Beyond Borders Global Biotechnology Report 2010

    Beyond borders Global biotechnology report 2010 To our clients and friends As economies around the world begin to recover from the worst diminished means, key constituents in the biotechnology economic crisis since the Great Depression, it is clear that a “new ecosystem — investors, pharmaceutical companies, payors, normal” is emerging. Among other things, this is a world in which governments and biotech firms — need to do more with less. capital flows are far more constrained than during the easy money- Companies that are able to develop creative solutions to boost fueled decade that preceded the downturn. What impact has this efficiency will be best positioned to succeed in the new normal. capital-constrained environment had on biotechnology — a business Readers of Beyond borders will notice some structural changes that is based on an enormous hunger for capital coupled with an in this year’s report. In prior years, we organized the report by exceptionally long path to commercial payback? geography, with sections on the Americas, Europe and Asia-Pacific. We set out to answer that question in this year’s Beyond borders. This year, we have instead organized the report thematically. As usual, we analyze key indicators of the industry’s performance: The Global perspective section brings together our point of view financing activity, deal trends, financial results, pipeline strength on salient trends and implications as well as some perspectives and product approvals. While the overall results are robust, the gap from company leaders. This is followed by a Country profiles between the industry’s haves and its have-nots has widened.
  • Pharmaceutical Company Contact Information (PDF)

    Pharmaceutical Company Contact Information (PDF)

    Pharmaceutical Company Contact Information - Rebate Filing - as of June 2018 Labeler Name Invoice Contact Phone Extension 00002 LILLY USA, LLC LISA NORTON (317) 276-2000 00003 ER SQUIBB AND SONS INC. LYNN LEWIS (609) 897-4731 00004 GENENTECH CONTRACT ADMINISTRATION (650) 866-2666 00005 LEDERLE LABORATORIES DAN MAGUIRE (484) 563-5097 00006 MERCK & CO., INC. DOUG BICKFORD (215) 652-0671 00007 SMITHKLINE BEECHAM DAVID BUCKLEY (215) 751-5690 00008 WYETH LABORATORIES JENNIFER WOOTEN (901) 215-1883 00009 PHARMACIA AND UPJOHN COMPANY/PFIZER JENNIFER WOOTEN (901) 215-1883 00013 PHARMACIA AND UPJOHN COMPANY NICHOLAS CHRISTODOULOU (336) 291-1053 00014 G. D. SEARLE & CO. CINDY MCDONALD (847) 581-5726 00015 MEAD JOHNSON AND COMPANY LYNN LEWIS (609) 897-4731 00016 PHARMACIA INC. BARBARA WINGET (908) 901-7254 00023 ALLERGAN INC SHOBHANA MINAWALA (714) 246-6205 00024 SANOFI WINTHROP PHARMACEUTICALS LAURIE DUNLAP, ADMIN., GOVT. OPERATIONS (212) 551-4198 00025 PHARMACIA CORPORATION NICHOLAS CHRISTODOULOU (336) 291-1053 00026 BAYER CORPORATION PHARMACEUTICAL DIV. LINDA WOLCHESKI (203) 812-6372 00028 NOVARTIS PHARMACEUTICALS (862) 778-8094 00029 SMITHKLINE BEECHAM DAVID BUCKLEY (215) 751-5690 00031 A. H. ROBINS COMPANY DAN MAGUIRE (610) 902-3222 00032 SOLVAY PHARMACEUTICALS STACEY LENOX (847) 937-3979 00033 SYNTEX LABORATORIES, INC. JANICE BRENNAN (973) 562-3494 00034 THE PURDUE FREDERICK COMPANY JUNE STOWE (203) 899-8035 00037 CARTER-WALLACE, INC. JAY R BRENNAN (609) 655-6163 00038 ASTRAZENECA LP DAVID WRIGHT (302) 886-2268 7820 00039 AVENTIS PHARMACEUTICALS (908) 981-7461 00043 NOVARTIS CONSUMER HEALTH, INC. EDWARD D. COLLINS (973) 781-6191 00044 KNOLL LABORATORIES DEBRA DEYOUNG (847) 937-4372 00045 MCNEIL PHARMACEUTICAL (908) 218-6777 00046 AYERST LABORATORIES (901) 215-1473 00047 WARNER CHILCOTT LABORATORIES LISA KAROLCHYK (973) 442-3262 00048 KNOLL PHARMACEUTICAL COMPANY DEBRA DEYOUNG (847) 937-4372 00049 ROERIG NICHOLAS CHRISTODOULOU (336) 291-1053 00051 UNIMED PHARMACEUTICALS, INC STACY LENOX (847) 937-3979 00052 ORGANON, USA, INC.